FY2029 EPS Estimates for Disc Medicine Lowered by Analyst

Key Points

• HC Wainwright lowered Disc Medicine’s FY2029 EPS estimate to $1.03 from $1.06, while maintaining a “Buy” rating and $120 price target. The firm projects FY2030 EPS of $7.34.
• Analyst sentiment remains broadly positive, with 10 Buy, one Hold, and one Sell rating, producing a consensus “Moderate Buy” rating and $106 price target.
• Disc Medicine recently reported a quarterly loss of $1.54 per share, better than the expected $1.71 loss. Institutional investors own 83.7% of the stock, while insiders have sold 105,712 shares worth about $7.6 million over the past 90 days.

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Investment analysts at HC Wainwright dropped their FY2029 earnings estimates for Disc Medicine in a report released on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $1.03 for the year, down from their previous forecast of $1.06. HC Wainwright currently has a "Buy" rating and a $120.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($6.62) per share. HC Wainwright also issued estimates for Disc Medicine's FY2030 earnings at $7.34 EPS.

Other analysts have also issued research reports about the company. Weiss Ratings restated a "sell (d-)" rating on shares of Disc Medicine in a report on Friday, July 17th. Wedbush reaffirmed an "outperform" rating and issued a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Morgan Stanley lifted their price target on Disc Medicine from $80.00 to $85.00 and gave the company an "overweight" rating in a report on Monday, June 15th. Finally, Wall Street Zen raised Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Disc Medicine currently has a consensus rating of "Moderate Buy" and a consensus price target of $106.00.

Disc Medicine Trading Down 1.9%

Disc Medicine stock opened at $77.44 on Friday. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00. The company has a 50 day moving average price of $73.44 and a 200 day moving average price of $69.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.71) by $0.17.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. lifted its holdings in Disc Medicine by 25.3% in the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after purchasing an additional 399,026 shares during the last quarter. Vanguard Group Inc. boosted its position in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock worth $140,371,000 after purchasing an additional 319,621 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. JPMorgan Chase & Co. grew its holdings in Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after purchasing an additional 828,248 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company's stock valued at $120,566,000 after purchasing an additional 108,197 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company's stock.

Insider Activity at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 33,000 shares of the stock in a transaction on Monday, July 13th. The shares were sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the transaction, the chief executive officer directly owned 226,064 shares of the company's stock, valued at $16,945,757.44. This represents a 12.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rahul Khara sold 1,649 shares of the firm's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $123,675.00. Following the transaction, the insider owned 52,173 shares in the company, valued at approximately $3,912,975. This trade represents a 3.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 105,712 shares of company stock valued at $7,597,536. Insiders own 3.76% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source